Compare ACADIA Pharmaceuticals Inc. (ACAD) vs DraftKings Inc (DKNG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs DraftKings Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while DraftKings Inc trades at $27.36 (market cap $13.35B). The key difference: DraftKings Inc is far larger — about 3× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, DraftKings Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | DKNG | |
|---|---|---|
Market Cap | $4.49B | $13.35B |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $48.23 |
52-Week Low | $20.06 | $20.72 |
Enterprise Value | $3.69B | $14.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
DraftKings (DKNG) trades at $26.91, up 3.94% today, with a bearish technical signal but strong analyst consensus. Revenue grew to $6.05B in 2025, achieving positive net income of $3.71M, a significant turnaround from prior losses. The launch of the DKeX prediction market exchange (Business Wire, 2026-06-26) and record sportsbook engagement during the 2026 World Cup (Benzinga, 2026-06-26) highlight growth initiatives, though profitability remains thin with a P/E of 291.22.
The outlook is mixed: robust revenue growth and a $34.25 analyst price target suggest upside, but high valuation, competitive pressures, and regulatory risks pose challenges. Positive cash flow from operations of $662.86M in 2025 supports stability, yet volatility near key resistance at $27 requires monitoring for sustained bullish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →
